If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Verzenio ® (abemaciclib) tablets50mg, 100mg, 150mg, 200mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Abemaciclib is indicated
Abemaciclib is an inhibitor of CDK4 and CDK6. These kinases are activated upon binding to D-cyclins. In ER+ breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the Rb, cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single agent or in combination with antiestrogens resulted in reduction of tumor size.1
1Verzenio [package insert]. Indianapolis, IN: Eli Lilly and Company; 2020.
CDK = cyclin-dependent kinase
ER+ = estrogen receptor-positive
ET = endocrine therapy
HER2- = human epidermal growth factor receptor 2-negative
HR+ = hormone receptor-positive
MBC = metastatic breast cancer
Rb = retinoblastoma protein
Date of Last Review: March 26, 2021